Cardiac safety of liposomal anthracyclines
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Toxicology,Molecular Biology
Link
http://link.springer.com/content/pdf/10.1007/s12012-007-0014-4.pdf
Reference10 articles.
1. Knoop, A. S. et al. (2005). Retrospective analysis of topoisomerase IIa amplifications and delections as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. Journal of Clinical Oncology, 23(30), 7483–7490.
2. Pritchard, K. I., Shepherd, L. E., O’Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., & Levine, M. N. (2006). National cancer institute of Canada clinical trials group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. The New England Journal of Medicine, 354(20), 2103–2111.
3. Slamon D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, 344, 783–792.
4. Swenson, C. E., Bolcsak, L. E., Batist, G., Guthrie, T. H. Jr Tkaczuk, K. H., Boxenbaum, H., Welles, L., Chow, S. C., Bhamra, R., & Chaikin, P. (2003). Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs, 14(3), 239–246.
5. Overmoyer, B., Silverman, P., Holder, L. W., Tripathy, D., & Henderson, I. C. (2005). Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clinical Breast Cancer, 6(2), 150–157.
Cited by 51 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review);Drug development & registration;2024-08-26
2. Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management;Journal of Clinical Medicine;2024-03-09
3. Liposomes in the Targeted Gene Therapy of Cancer: A Critical Review;Current Drug Delivery;2023-05
4. Recent advances and futuristic potentials of nano-tailored doxorubicin for prostate cancer therapy;Journal of Drug Delivery Science and Technology;2023-03
5. A polymeric micellar drug delivery system developed through a design of Experiment approach improves pancreatic tumor accumulation of calcipotriol and paclitaxel;International Journal of Pharmaceutics;2021-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3